RU2013131241A - Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака - Google Patents
Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака Download PDFInfo
- Publication number
- RU2013131241A RU2013131241A RU2013131241/15A RU2013131241A RU2013131241A RU 2013131241 A RU2013131241 A RU 2013131241A RU 2013131241/15 A RU2013131241/15 A RU 2013131241/15A RU 2013131241 A RU2013131241 A RU 2013131241A RU 2013131241 A RU2013131241 A RU 2013131241A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- formula
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42146510P | 2010-12-09 | 2010-12-09 | |
| US61/421,465 | 2010-12-09 | ||
| US201161436258P | 2011-01-26 | 2011-01-26 | |
| US61/436,258 | 2011-01-26 | ||
| US201161467485P | 2011-03-25 | 2011-03-25 | |
| US61/467,485 | 2011-03-25 | ||
| FR1159940 | 2011-11-03 | ||
| FR1159940 | 2011-11-03 | ||
| PCT/US2011/063871 WO2012078832A1 (en) | 2010-12-09 | 2011-12-08 | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013131241A true RU2013131241A (ru) | 2015-01-20 |
Family
ID=45464841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013131241/15A RU2013131241A (ru) | 2010-12-09 | 2011-12-08 | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140024653A1 (enExample) |
| EP (1) | EP2648729A1 (enExample) |
| JP (1) | JP2013544892A (enExample) |
| KR (1) | KR20140011311A (enExample) |
| CN (1) | CN103402518A (enExample) |
| AR (1) | AR084216A1 (enExample) |
| AU (1) | AU2011338354A1 (enExample) |
| BR (1) | BR112013014198A2 (enExample) |
| CA (1) | CA2820748A1 (enExample) |
| CL (1) | CL2013001643A1 (enExample) |
| CR (1) | CR20130246A (enExample) |
| DO (1) | DOP2013000131A (enExample) |
| MA (1) | MA34815B1 (enExample) |
| MX (1) | MX2013006319A (enExample) |
| NZ (1) | NZ611581A (enExample) |
| PE (1) | PE20140702A1 (enExample) |
| PH (1) | PH12013501163A1 (enExample) |
| RU (1) | RU2013131241A (enExample) |
| SG (1) | SG190368A1 (enExample) |
| TW (1) | TW201306837A (enExample) |
| UY (1) | UY33790A (enExample) |
| WO (1) | WO2012078832A1 (enExample) |
| ZA (1) | ZA201303687B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104334192A (zh) * | 2012-04-06 | 2015-02-04 | 赛诺菲 | 使用pi3k抑制剂和mek抑制剂治疗癌症的方法 |
| JP2015536910A (ja) * | 2012-10-11 | 2015-12-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 抗がん活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体とｍｅｋインヒビターとの組み合わせ |
| ES2779975T3 (es) | 2014-02-07 | 2020-08-21 | Verastem Inc | Métodos y composiciones para tratar el crecimiento celular anormal |
| WO2016014390A1 (en) * | 2014-07-25 | 2016-01-28 | Merck Patent Gmbh | Compositions and methods for mek inhibitor combination therapy in the treatment of cancer |
| CA3085693A1 (en) * | 2017-12-22 | 2019-06-27 | Adienne S.A. | Quantitative cellular method for determining the biological activity of an anti-cd26 ligand |
| WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| WO2022082078A1 (en) * | 2020-10-16 | 2022-04-21 | Memorial Sloan Kettering Cancer Center | Induction of ferroptosis for cancer therapy |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
-
2011
- 2011-12-07 AR ARP110104595A patent/AR084216A1/es unknown
- 2011-12-08 KR KR1020137017879A patent/KR20140011311A/ko not_active Withdrawn
- 2011-12-08 CN CN2011800671706A patent/CN103402518A/zh active Pending
- 2011-12-08 SG SG2013039367A patent/SG190368A1/en unknown
- 2011-12-08 PE PE2013001394A patent/PE20140702A1/es not_active Application Discontinuation
- 2011-12-08 EP EP11806025.0A patent/EP2648729A1/en not_active Withdrawn
- 2011-12-08 MA MA36091A patent/MA34815B1/fr unknown
- 2011-12-08 JP JP2013543331A patent/JP2013544892A/ja not_active Abandoned
- 2011-12-08 RU RU2013131241/15A patent/RU2013131241A/ru not_active Application Discontinuation
- 2011-12-08 CA CA2820748A patent/CA2820748A1/en not_active Abandoned
- 2011-12-08 AU AU2011338354A patent/AU2011338354A1/en not_active Abandoned
- 2011-12-08 TW TW100145212A patent/TW201306837A/zh unknown
- 2011-12-08 WO PCT/US2011/063871 patent/WO2012078832A1/en not_active Ceased
- 2011-12-08 MX MX2013006319A patent/MX2013006319A/es not_active Application Discontinuation
- 2011-12-08 PH PH1/2013/501163A patent/PH12013501163A1/en unknown
- 2011-12-08 BR BR112013014198A patent/BR112013014198A2/pt not_active IP Right Cessation
- 2011-12-08 NZ NZ611581A patent/NZ611581A/en not_active IP Right Cessation
- 2011-12-09 UY UY0001033790A patent/UY33790A/es not_active Application Discontinuation
-
2013
- 2013-05-21 ZA ZA2013/03687A patent/ZA201303687B/en unknown
- 2013-05-27 CR CR20130246A patent/CR20130246A/es unknown
- 2013-06-07 US US13/912,647 patent/US20140024653A1/en not_active Abandoned
- 2013-06-07 CL CL2013001643A patent/CL2013001643A1/es unknown
- 2013-06-07 DO DO2013000131A patent/DOP2013000131A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20140702A1 (es) | 2014-06-26 |
| CR20130246A (es) | 2013-09-03 |
| WO2012078832A1 (en) | 2012-06-14 |
| CA2820748A1 (en) | 2012-06-14 |
| MA34815B1 (fr) | 2014-01-02 |
| CL2013001643A1 (es) | 2014-03-28 |
| AU2011338354A1 (en) | 2013-06-27 |
| TW201306837A (zh) | 2013-02-16 |
| EP2648729A1 (en) | 2013-10-16 |
| BR112013014198A2 (pt) | 2016-09-13 |
| JP2013544892A (ja) | 2013-12-19 |
| ZA201303687B (en) | 2014-01-29 |
| AR084216A1 (es) | 2013-05-02 |
| SG190368A1 (en) | 2013-06-28 |
| KR20140011311A (ko) | 2014-01-28 |
| NZ611581A (en) | 2015-02-27 |
| US20140024653A1 (en) | 2014-01-23 |
| CN103402518A (zh) | 2013-11-20 |
| DOP2013000131A (es) | 2013-11-15 |
| PH12013501163A1 (en) | 2013-07-29 |
| UY33790A (es) | 2012-07-31 |
| MX2013006319A (es) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| RU2016102158A (ru) | Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| MX2012010226A (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
| RU2015125307A (ru) | Комбинированная терапия | |
| RU2013147514A (ru) | Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| UA124238U (uk) | Спосіб лікування раку молочної залози | |
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| JP2013544892A5 (enExample) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
| JP2016528238A (ja) | イソチオシアネート系化合物と抗癌薬の併用 | |
| EA201101302A1 (ru) | Фармацевтические комбинации, содержащие rdea119/bay 869766, для лечения специфических злокачественных новообразований | |
| RU2015105821A (ru) | Способ адъювантного лечения рака | |
| RU2013148817A (ru) | Комбинации соединений-ингибиторов акт и мек и способы их применения | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| JP2014530181A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160328 |